Shigella flexneri serotype 1 infections in men who have sex with men in Vancouver, Canada.

Abstract:

OBJECTIVES:Outbreaks of shigellosis have been documented in men who have sex with men (MSM), associated with interpersonal transmission and underlying HIV infection. We observed a rise in Shigella flexneri isolates identified in a downtown tertiary-care hospital laboratory located within the city centre community health area (CHA-1) of Vancouver, Canada. The objectives of this study were to evaluate clinical outcomes of shigellosis cases among MSM admitted to hospital and to evaluate trends in Shigella cases within Vancouver, Canada. METHODS:Adult rates of shigellosis were analysed by gender and health region, from 2005 to 2011, followed by retrospective chart review of all hospital laboratory-identified S. flexneri cases from 2008 to 2012. Serotyping and pulsed-field gel electrophoresis (PFGE) were performed on these isolates. RESULTS:Although shigellosis rates in men within CHA-1 did not change from 2005 to 2011 (range 33.4-68.5 per 100 000; P = 0.74), they were significantly higher than in other regions within the city of Vancouver (P ≤ 0.001) and the province of British Columbia (P ≤ 0.001). Shigella flexneri rates in men within CHA-1 increased significantly (range 2.3-51.4 per 100 000; P < 0.001), starting in 2008, and were higher than in other regions within Vancouver (P ≤ 0.01). Seventy-nine isolates of S. flexneri from 72 patients were identified by a single hospital laboratory. All patients were male and predominantly MSM (91.7%) and HIV-infected (86.1%), with most (92.6%) demonstrating CD4 counts ≥ 200 cells/μL. In total, 38.0% required hospitalization. Most (87.3%) had S. flexneri serotype 1 infection, with 72.9% of these representing a single PFGE pattern. CONCLUSIONS:We identified high levels of transmission of a primarily clonal strain of S. flexneri serotype 1 in our local MSM population, resulting in a substantial burden of illness and health care resource use secondary to hospital admissions.

journal_name

HIV Med

journal_title

HIV medicine

authors

Wilmer A,Romney MG,Gustafson R,Sandhu J,Chu T,Ng C,Hoang L,Champagne S,Hull MW

doi

10.1111/hiv.12191

subject

Has Abstract

pub_date

2015-03-01 00:00:00

pages

168-75

issue

3

eissn

1464-2662

issn

1468-1293

journal_volume

16

pub_type

杂志文章
  • Kaposi's sarcoma in HIV-infected patients: treatment options.

    abstract::Kaposi's sarcoma (KS) is the most prevalent AIDS-associated tumour, occurring in 20-30% of HIV-1-infected individuals in the early 1980s. The introduction of highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of the disease and might therefore support the concept of 'opportunistic mali...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1046/j.1468-1293.2000.00027.x

    authors: Hermans P

    更新日期:2000-07-01 00:00:00

  • Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.

    abstract:BACKGROUND:The world-wide AIDS epidemic is reflected in Western Europe in an increasing number of HIV-infected persons who originate from Africa. We describe the characteristics and response to antiretroviral therapy (ART) of HIV-infected patients born in Africa and living in France. METHODS:Analysis of data from the ...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2007.00447.x

    authors: Breton G,Lewden C,Spire B,Salmon D,Brun-Vézinet F,Duong M,Allavena C,Leport C,Salamon R,APROCO COPILOTE ANRS CO8 Study Group.

    更新日期:2007-04-01 00:00:00

  • Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010.

    abstract:OBJECTIVES:Adipose tissue affects several aspects of the cellular immune system, but prior epidemiological studies have differed on whether a higher body mass index (BMI) promotes CD4 T-cell recovery on antiretroviral therapy (ART). The objective of this analysis was to assess the relationship between BMI at ART initia...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12259

    authors: Koethe JR,Jenkins CA,Lau B,Shepherd BE,Silverberg MJ,Brown TT,Blashill AJ,Anema A,Willig A,Stinnette S,Napravnik S,Gill J,Crane HM,Sterling TR,North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

    更新日期:2015-10-01 00:00:00

  • Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study.

    abstract:OBJECTIVE:The aim of the study was to characterize and compare insulin resistance (IR) in hepatitis C virus (HCV)-antibody (Ab)-positive and HCV-Ab-negative patients with HIV infection. METHODS:This was a single-centre cross-sectional study of 1041 HIV-infected patients (373 HCV-Ab-positive; 167 with detectable plasma...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2007.00539.x

    authors: Squillace N,Lapadula G,Torti C,Orlando G,Mandalia S,Nardini G,Beghetto B,Costarelli S,Guaraldi G

    更新日期:2008-03-01 00:00:00

  • Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland.

    abstract:OBJECTIVES:Despite the huge success of antiretroviral therapy (ART), there is an ongoing HIV epidemic among men who have sex with men (MSM) in resource-rich countries. Understanding the driving factors underlying this process is important for curbing the epidemic. METHODS:We simulated the HIV epidemic in MSM in Switze...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12660

    authors: Kusejko K,Marzel A,Hampel B,Bachmann N,Nguyen H,Fehr J,Braun DL,Battegay M,Bernasconi E,Calmy A,Cavassini M,Hoffmann M,Böni J,Yerly S,Klimkait T,Perreau M,Rauch A,Günthard HF,Kouyos RD,Swiss HIV Cohort Study.

    更新日期:2018-11-01 00:00:00

  • Chronic hepatitis B increases mortality and complexity among HIV-coinfected patients in South Africa: a cohort study.

    abstract:OBJECTIVES:To assess the effect of chronic hepatitis B on survival and clinical complexity among people living with HIV following antiretroviral therapy (ART) initiation. METHODS:We evaluated mortality and single-drug substitutions up to 3 years from ART initiation (median follow-up 2.75 years; interquartile range 2-3...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12367

    authors: Velen K,Charalambous S,Innes C,Churchyard GJ,Hoffmann CJ

    更新日期:2016-10-01 00:00:00

  • Appendicitis in HIV-infected patients during the era of highly active antiretroviral therapy.

    abstract:BACKGROUND:Limited studies have suggested increased incidence rates and unusual clinical presentations of appendicitis among HIV-infected patients during the pre-highly active antiretroviral therapy (HAART) era. Data in the HAART era are sparse, and no study has evaluated potential HIV-related risk factors for the deve...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2008.00577.x

    authors: Crum-Cianflone N,Weekes J,Bavaro M

    更新日期:2008-07-01 00:00:00

  • Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.

    abstract:OBJECTIVES:The aim of the study was to compare the effects on lipids, body composition and renal function of once-daily ritonavir-boosted saquinavir (SQV/r) or atazanavir (ATV/r) in combination with tenofovir/emtricitabine (TDF/FTC) over 48 weeks. METHODS:An investigator-initiated, randomized, open-label, multinationa...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2011.00941.x

    authors: Vrouenraets SM,Wit FW,Fernandez Garcia E,Moyle GJ,Jackson AG,Allavena C,Raffi F,Jayaweera DT,Mauss S,Katlama C,Fisher M,Slama L,Hardy WD,Dejesus E,van Eeden A,Reiss P,BASIC Study Group.

    更新日期:2011-11-01 00:00:00

  • HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality.

    abstract:OBJECTIVES:Hepatitis C virus (HCV) has emerged as an important health problem in the era of effective HIV treatment. However, very few data exist on the health status and disease burden of HIV/HCV-coinfected Canadians. METHODS:HIV/HCV-coinfected patients were enrolled prospectively in a multicentre cohort from 16 cent...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2012.01028.x

    authors: Klein MB,Rollet KC,Saeed S,Cox J,Potter M,Cohen J,Conway B,Cooper C,Côté P,Gill J,Haase D,Haider S,Hull M,Moodie E,Montaner J,Pick N,Rachlis A,Rouleau D,Sandre R,Tyndall M,Walmsley S,Canadian HIV-HCV Cohort Inve

    更新日期:2013-01-01 00:00:00

  • CD4:CD8 ratio in children with perinatally acquired HIV-1 infection.

    abstract:OBJECTIVES:In adults with horizontally acquired HIV infection, an inverted CD4:CD8 ratio is associated with persistent immune activation, size of HIV reservoir and predicts an increased risk of non-AIDS-defining adverse events. Normalization of this ratio with antiretroviral therapy (ART) is suboptimal in adults, despi...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12642

    authors: Seers T,Vassallo P,Pollock K,Thornhill JP,Fidler S,Foster C

    更新日期:2018-10-01 00:00:00

  • Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice.

    abstract:OBJECTIVES:Effective HIV therapy reflects suppression of plasma HIV RNA levels below assay detection thresholds, although lower levels of "residual viraemia" have also been demonstrated over extended periods of effective antiretroviral treatment. Here we examine the determinants of HIV RNA suppression below the standar...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12323

    authors: McKinnon E,Castley A,Payne L,Pummer S,Nolan D

    更新日期:2016-08-01 00:00:00

  • An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.

    abstract:OBJECTIVES:Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, is a drug that is frequently included in highly active antiretroviral therapy for treatment of HIV infection. Decreased bioavailability and increased toxicity limit its use. We report a formulation of efavirenz-loaded lactoferrin nanoparticle...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12475

    authors: Kumar P,Lakshmi YS,Kondapi AK

    更新日期:2017-08-01 00:00:00

  • Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE s

    abstract:OBJECTIVES:We assessed whether changes at week 12 in markers of bone turnover, inflammation, and immune activation were associated with clinically important (≥ 5%) bone mineral density (BMD) loss from baseline to week 48 at the proximal femur (hip) and lumbar spine in the SECOND-LINE study. METHODS:We measured concent...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12882

    authors: Mwasakifwa GE,Amin J,White CP,Center JR,Kelleher A,Boyd MA

    更新日期:2020-09-01 00:00:00

  • Paediatric antiretroviral therapy audit in South London.

    abstract:OBJECTIVES:To audit clinical and surrogate marker outcome data following the introduction of combination antiretroviral therapy to HIV-infected children in South London. METHODS:We performed a retrospective cohort study of 110 HIV-infected children under the care of the Paediatric HIV in South London Network (PHILS-NE...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1464-2662.2001.00098.x

    authors: Doerholt K,Sharland M,Ball C,DuMont G

    更新日期:2002-01-01 00:00:00

  • Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis.

    abstract::Despite advances in the treatment of HIV disease, the incidence and mortality of invasive cryptococcal disease remain significant. A matched, case-control study was performed to examine the impact of highly active antiretroviral therapy (HAART) and azole use on the incidence of invasive cryptococcal disease in HIV-inf...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2005.00289.x

    authors: Cantey PT,Stephens DS,Rimland D

    更新日期:2005-07-01 00:00:00

  • The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.

    abstract:OBJECTIVE:The aim of the study was to compare the metabolic and morphological effects of enfuvirtide plus an optimized background (OB) regimen vs. OB alone (control group) in treatment-experienced patients in the T-20 vs. Optimized Regimen Only (TORO) studies. METHODS:Body composition and metabolic changes were invest...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2010.00845.x

    authors: Cooper DA,Cordery DV,Reiss P,Henry K,Nelson M,O'Hearn M,Reynes J,Arastéh K,Chung J,Rowell L,Guimaraes D,Bertasso A,TORO 1 and TORO 2 Study Groups.

    更新日期:2011-01-01 00:00:00

  • Effect of testing experience and profession on provider acceptability of rapid HIV testing after implementation in public sexual health clinics in Sydney.

    abstract:OBJECTIVES:Rapid HIV testing (RHT) is well established in many countries, but it is new in Australia since a policy change in 2011. We assessed service provider acceptability of RHT before and after its implementation in four Sydney public sexual health clinics. METHODS:Service providers were surveyed immediately afte...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12209

    authors: Conway DP,Guy R,McNulty A,Couldwell DL,Davies SC,Smith DE,Keen P,Cunningham P,Holt M,Sydney Rapid HIV Test Study.

    更新日期:2015-05-01 00:00:00

  • Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes.

    abstract:OBJECTIVES:Antiretroviral therapy (ART) has been associated with unfavourable lipid profile changes and increased risk of cardiovascular disease (CVD). With a growing population on ART in South Africa, there has been concern about the increase in noncommunicable diseases such as CVD. We determined risk factors associat...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12495

    authors: Jamieson L,Evans D,Brennan AT,Moyo F,Spencer D,Mahomed K,Maskew M,Long L,Rosen S,Fox MP

    更新日期:2017-09-01 00:00:00

  • Cushing's syndrome secondary to inhaled corticosteroids mimicking HIV-associated lipodystrophy.

    abstract::We report the case of an asthmatic man with HIV infection who was initially diagnosed with HIV treatment-associated lipodystrophy. Further investigations showed he had Cushing's syndrome secondary to 1600 microg of budesonide dry powder inhaler. Cushing's syndrome has not been reported previously on this normal dose o...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1468-1293.2001.00058.x

    authors: le Roux CW,Beckles MA,Besser GM,Pinching AJ,Davison AG

    更新日期:2001-04-01 00:00:00

  • Is PEP prescribed appropriately?

    abstract::We describe the characteristics of HIV post-exposure prophylaxis (PEP) recipients and PEP indications at 56 Dean Street, a central London sexual health clinic. PEP was prescribed on 577 occasions. Most (97%) was given for unprotected anal intercourse. Over a fifth of exposures involved recreational drug use. Of the pa...

    journal_title:HIV medicine

    pub_type: 信件

    doi:10.1111/hiv.12275

    authors: Whitlock G,Nwokolo N,McOwan A

    更新日期:2015-09-01 00:00:00

  • HIV/hepatitis C virus and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia.

    abstract:INTRODUCTION:Hyperlipidaemia is a recognized complication of HIV antiretroviral therapy. The interactions among HIV, viral hepatitis, antiretroviral therapies and lipids are poorly understood. METHODS:Ontario HIV Treatment Network Cohort Study participants with at least one lipid level after highly active antiretrovir...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2010.00897.x

    authors: Diong C,Raboud J,Li M,Cooper C,Ontario HIV Treatment Network Cohort Study Team.

    更新日期:2011-08-01 00:00:00

  • Better preserved immune responses after immunization with rgp 160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up.

    abstract:OBJECTIVE:To study the impact of effective highly active antiretroviral therapy (HAART) on the preservation of long-term CD4 memory cells induced by vaccines in HIV-1-infected patients. METHODS:Thirty HIV-1-positive patients on HAART with undetectable viral load were randomized into three groups: 10 received HIV-1 rgp...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1468-1293.2003.00148.x

    authors: Hejdeman B,Leandersson AC,Fredriksson EL,Sandström E,Wahren B,Bratt G

    更新日期:2003-04-01 00:00:00

  • Monitoring the HIV continuum of care in key populations across Europe and Central Asia.

    abstract:OBJECTIVES:The aim of the study was to measure and compare national continuum of HIV care estimates in Europe and Central Asia in three key subpopulations: men who have sex with men (MSM), people who inject drugs (PWID) and migrants. METHODS:Responses to a 2016 European Centre for Disease Prevention and Control (ECDC)...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12603

    authors: Brown AE,Attawell K,Hales D,Rice BD,Pharris A,Supervie V,Van Beckhoven D,Delpech VC,An der Heiden M,Marcus U,Maly M,Noori T

    更新日期:2018-05-08 00:00:00

  • A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.

    abstract:OBJECTIVES:To compare the safety and efficacy of amprenavir [APV/j Agenerase trade mark; GlaxoSmithKline, [Ware, UK; 600 mg twice a day (bid)] boosted with low-dose ritonavir (RTV, 100 mg bid) with those of other protease inhibitors (PIs) in PI-experienced HIV-infected patients. STUDY DESIGN:Parallel-group, randomized...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2004.00224.x

    authors: Pulido F,Katlama C,Marquez M,Thomas R,Clumeck N,Pedro Rde J,Cattelan AM,Zhu C,Tymkewycz P

    更新日期:2004-07-01 00:00:00

  • Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.

    abstract:OBJECTIVES:The aim of the study was to compare the neuropsychiatric safety and tolerability of rilpivirine (TMC278) vs. efavirenz in a preplanned pooled analysis of data from the ECHO and THRIVE studies which compared the safety and efficacy of the two drugs in HIV-1 infected treatment naïve adults. METHODS:ECHO and T...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12012

    authors: Mills AM,Antinori A,Clotet B,Fourie J,Herrera G,Hicks C,Madruga JV,Vanveggel S,Stevens M,Boven K,ECHO and THRIVE study groups.

    更新日期:2013-08-01 00:00:00

  • Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.

    abstract:OBJECTIVES:TMC125-C227, an exploratory phase II, randomized, controlled, open-label trial, compared the efficacy and safety of TMC125 (etravirine) with an investigator-selected protease inhibitor (PI) in nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant, protease inhibitor-naïve, HIV-1-infected patients. ...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2008.00644.x

    authors: Ruxrungtham K,Pedro RJ,Latiff GH,Conradie F,Domingo P,Lupo S,Pumpradit W,Vingerhoets JH,Peeters M,Peeters I,Kakuda TN,De Smedt G,Woodfall B,TMC125-C227 study group.

    更新日期:2008-11-01 00:00:00

  • Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis.

    abstract:OBJECTIVES:The aim was to determine the effectiveness of the serum cryptococcal antigen (CrAg) test in the diagnosis of concurrent cryptococcal meningitis (CM) and as a predictor of mortality in HIV-infected patients. METHODS:In this retrospective study, all HIV-infected patients admitted to Shanghai Public Health Cli...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12679

    authors: Chen J,Zhang R,Shen Y,Liu L,Qi T,Wang Z,Mehraj V,Routy JP,Lu H

    更新日期:2019-01-01 00:00:00

  • Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.

    abstract:OBJECTIVES:The aim of the study was to describe growth and body composition changes in HIV-positive children after they had initiated or changed antiretroviral therapy (ART) and to correlate these with viral, immune and treatment parameters. METHODS:Ninety-seven prepubertal HIV-positive children were observed over 48 ...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2010.00823.x

    authors: Chantry CJ,Cervia JS,Hughes MD,Alvero C,Hodge J,Borum P,Moye J Jr,PACTG 1010 Team.

    更新日期:2010-10-01 00:00:00

  • Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study.

    abstract:OBJECTIVE:Data from observational cohorts may be influenced by population structure and loss to follow-up (LTFU). Quality of care may be associated with participation in cohort networks. We aimed to study the participation, characteristics and retention rates of immigrants in the Swiss HIV Cohort Study (SHCS). METHODS...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2011.00949.x

    authors: Thierfelder C,Weber R,Elzi L,Furrer H,Cavassini M,Calmy A,Bernasconi E,Gutmann C,Ledergerber B,Swiss HIV Cohort Study Group.

    更新日期:2012-02-01 00:00:00

  • The case for indicator condition-guided HIV screening.

    abstract::One-half of the estimated 2.5 million people who now live with HIV in the World Health Organization (WHO) European Region are still diagnosed late. A central question is which clinical scenarios should trigger an HIV test recommendation in order to avoid late presentation. Drawing on the work of the HIV Indicator Dise...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12022

    authors: Lazarus JV,Hoekstra M,Raben D,Delpech V,Coenen T,Lundgren JD,HIV in Europe Initiative Steering Committee.

    更新日期:2013-08-01 00:00:00